HOME >> MEDICINE >> NEWS
ACE inhibitors help preserve kidney function in IgA nephropathy

For young patients with the kidney disease IgA nephropathy (IgAN), early treatment with angiotensin-converting enzyme (ACE) inhibitors can reduce the long-term risk of irreversible kidney damage, suggests a study in the June Journal of the American Society of Nephrology.

"These results in young patients are of particular interest because they could offer a way of limiting the future need for renal replacement therapy in patients with IgAN," comments Dr. Rosanna Coppo of Regina Margherita Hospital in Turin, Italy, lead author of the new study.

In the European cooperative study (supported by EU Community), 66 children and young adults with early-stage IgAN were randomly assigned to treatment with the ACE inhibitor benazepril or an inactive placebo. IgA nephropathy is caused by deposits of the protein IgAan immune system antibodywithin the filtering units of the kidney (glomeruli). The abnormal IgA deposits damage the glomeruli, leading to blood and protein in the urine. The disease can progress over time, eventually requiring dialysis or transplantation to replace lost kidney function.

Favorable effects have been reported using corticosteroids, which can reduce proteinuria and decline of renal function. However, there are concerns about using steroids at high doses or for prolonged periods, particularly in children and young subjects. The patients in the study all had relatively mild disease, with normal or near-normal kidney function and only mildly elevated levels of protein in the urine. "Our trial focused on a subset of patients with a sort of 'pure' IgAN, without the confounding effects of aging or environmental toxic exposures, including smoking and alcohol, and without severe high blood pressure," says Dr. Coppo.

After a median three years of treatment, the rate of decreased kidney function was just three percent for patients treated with the ACE inhibitor, compared to fifteen percent in the placebo group. The combine
'"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology
16-May-2007


Page: 1 2

Related medicine news :

1. COX inhibitors may weaken protective qualities of estrogen hormone therapy
2. Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs
3. Selective serotonin reuptake inhibitors antidepressants and risk of violent behavior
4. COX-2 inhibitors prescribed to reduce gastrointestinal toxicity prior to the market withdrawals
5. First trimester use of ACE inhibitors implicated in birth defects
6. Researchers resolve how COX inhibitors cause heart hazards, and offer alternative treatment strategy
7. ACE inhibitors may reduce death, heart attack and stroke in patients with coronary artery disease
8. COX-2 inhibitors significantly reduce risk of cancer
9. Regular use of selective COX-2 inhibitors decreases risk of breast cancer
10. Race/ethnicity predict lipids, heart-disease risk in HIV-1 patients on protease inhibitors
11. Blocking previously unrecognized links between inflammatory systems could make COX-2 inhibitors safe

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ACE inhibitors help preserve kidney function IgA nephropathy

(Date:5/20/2013)... (HealthDay News) -- Although many hospital intensive care ... to help improve outcomes, new research suggests this ... Since one-third of teaching hospitals in the United ... a nighttime physician in the ICU, the practice ... away from hospitals with fewer resources, the study ...
(Date:5/20/2013)... Serena Gordon HealthDay Reporter , , MONDAY, May ... cough that was phased out in the late 1990s ... vaccine, a new study contends. Teenagers who received ... vaccine -- before they were 2 years old were ... during a recent outbreak in California, compared to children ...
(Date:5/20/2013)... Posterior fossa subdural hematoma (PFSDH) is a serious ... deliveries. But with appropriate treatment, there,s an excellent chance ... PFSDH, reports a study in the May issue of ... Congress of Neurological Surgeons . The journal is ... part of Wolters Kluwer Health . , The ...
(Date:5/20/2013)... toothpaste that transforms the sweet flavor of orange juice ... mysterious sensory phenomenon in colorful, animated detail ... award-winning Bytesize Science video series at ... scientific society, explains that the mainstay ingredients in toothpaste ... for short. When you brush your teeth, SLS produces ...
(Date:5/20/2013)... A new "telerehabilitation" approach lets physical therapists assess patients ... good accuracy compared with face-to-face examinations, reports a study ... . The journal is published by ... Wolters Kluwer Health . , Taking advantage of Skype ... feasible alternative to in-person clinic visits, according to the ...
Breaking Medicine News(10 mins):Health News:Nighttime Docs at ICUs Don't Boost Patient Outcomes: Study 2Health News:Study: Older Whooping Cough Vaccine More Effective 2Health News:Study: Older Whooping Cough Vaccine More Effective 3Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 3Health News:Telerehabilitation allows accurate assessment of patients with low back pain 2Health News:Telerehabilitation allows accurate assessment of patients with low back pain 3
(Date:5/20/2013)... Enrollment of patients with Type 2 diabetes ... trial of product candidate NewMet ™, a delayed-release ... 2 diabetes. Elcelyx expects to complete enrollment of 240 ... of the trial,s primary endpoint of change in fasting ... read-out for long-term glucose lowering and weight benefits is ...
(Date:5/20/2013)...  Medicare Part D seniors in plans with ... costs, convenient access to pharmacies and other benefits, ... Associates released today by the Pharmaceutical Care Management ... seniors (9.5 million) are currently enrolled in plans ... lower costs, pharmacy choices, and overall value of ...
(Date:5/19/2013)... , May 20, 2013 Claret Medical, Inc. ... Nicolas Van Mieghem et al., Histopathology ... Published ahead of print in Circulation, May 7 th ... Medical Center, Rotterdam, the Netherlands and ... of the Cardiovascular Pathology Institute, Gaithersburg, Maryland.  ...
Breaking Medicine Technology:Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR 2
Cached News: